Destiny Pharma announces start of new oral mucositis research program

Oral mucositis is a common and devastating complication from chemotherapy and radiotherapy suffered by more than 2 million cancer patients every year.

Destiny Pharma plc, a clinical-stage biotech company focused on the development of novel medicines that can prevent life-threatening infections, has started a new research program on the condition. 

The research study will be conducted in the US by oral mucositis (OM) expert Stephen Sonis, and will investigate the potential of XF-73 as a preventive medicine to alleviate suffering from OM in patients receiving cancer treatment by testing its efficacy in the gold-standard model of OM.

The potential utility of XF-73 in this indication is due to the association between the development of OM and changes in the oral microbiome

The antimicrobial properties of XF‑73 have already been demonstrated in phase 2 clinical trials. As well as having fast-acting antimicrobial activity and a novel mechanism of action, XF-73 has an excellent safety profile and a lack of systemic exposure which means that it is ideally suited for development as an innovative oral formulation to reduce the severity of OM. 

The post Destiny Pharma announces start of new oral mucositis research program appeared first on

© Labiotech UG and Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and with appropriate and specific direction to the original content.


About the Author: Biotech Today

You might like